Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Neurosurg ; 114(5): 1471-8, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21214327

RESUMEN

OBJECT: The normalization of increased intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI) is assumed to limit secondary brain injury and improve outcome. Despite evidence-based recommendations for monitoring and treatment of elevated ICP, there are few studies that show an association between response to ICP-directed therapeutic regimens and adjusted mortality rate. This study utilizes a large prospective database to examine the effect of response to ICP-lowering therapy on risk of death within the first 2 weeks of injury in patients who sustained TBI and are older than 16 years. METHODS: The current study is based on 1426 patients with severe TBI (Glasgow Coma Scale [GCS] score < 9) of whom 388 were treated for elevated ICP (> 25 mm Hg) between 2000 and 2008 at 22 trauma centers enrolled in a New York State quality improvement program. This prospectively collected database also contains information including age, admission GCS score, pupillary status, CT scanning parameters, and hypotension, which are all known early prognostic indicators of death. Treatment of elevated ICP consisted of administration of mannitol, hypertonic saline, barbiturates, and/or drainage of CSF or decompressive craniectomy. The factors predicting ICP response to treatment and predicting death at 2 weeks were evaluated using logistic regression analyses. RESULTS: Increasing age and fewer hours of elevated ICP on Day 1 were found to be significant predictors (p = 0.001 and 0.0003, respectively) of a positive response to treatment. Response to ICP-lowering therapy (p = 0.03), younger age (p < 0.0001), fewer hours of elevated ICP (p < 0.0001), and absence of arterial hypotension on Day 1 (p = 0.001) significantly predicted reduced risk of death. CONCLUSIONS: Patients who responded to ICP-lowering treatment had a 64% lower risk of death at 2 weeks than those who did not respond after adjusting for factors that independently predict risk of death.


Asunto(s)
Lesiones Encefálicas/fisiopatología , Lesiones Encefálicas/terapia , Hipertensión Intracraneal/fisiopatología , Hipertensión Intracraneal/terapia , Presión Intracraneal/fisiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Barbitúricos/administración & dosificación , Lesiones Encefálicas/mortalidad , Craneotomía , Descompresión Quirúrgica , Femenino , Escala de Coma de Glasgow , Humanos , Hipertensión Intracraneal/mortalidad , Presión Intracraneal/efectos de los fármacos , Modelos Logísticos , Masculino , Manitol/administración & dosificación , Persona de Mediana Edad , Análisis Multivariante , New York , Pronóstico , Estudios Retrospectivos , Riesgo , Solución Salina Hipertónica/administración & dosificación , Punción Espinal , Tasa de Supervivencia , Tomografía Computarizada por Rayos X , Centros Traumatológicos , Adulto Joven
2.
Crit Care Med ; 37(4): 1433-41, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19242317

RESUMEN

OBJECTIVE: To evaluate potential side effects of continuous hypertonic 3% saline (CHS) as maintenance fluid in patients with brain injury. METHODS: Retrospective chart analysis of prospectively collected data. PATIENTS: Patients admitted to the neurosurgical intensive care unit for >4 days with traumatic brain injury, stroke, or subarachnoid hemorrhage with a Glasgow Coma Scale <9 and elevated intracranial pressure (ICP) or at risk of developing elevated ICP were included. Based on physician preference, one group was treated with 3% CHS at a rate of 1.5 mL/kg/bw as maintenance fluid. The other group received 0.9% normal saline (NS). Two percent saline was used in the CHS group to wean patients off 3% CHS or when sodium was above 155. Data on serum sodium, blood urea nitrogen, creatinine, ICP, infection rate, length of stay, rates of deep vein thrombosis, and pulmonary emboli and dural thrombosis were collected prospectively. RESULTS: One hundred seven patients in the CHS group and 80 in the NS group met the inclusion criteria. The incidence of moderate hypernatremia (Na >155 mmol/L) and severe hypernatremia (Na >160 mmol/L) was significantly higher in the CHS therapy group than in the NS group. No significant relationship between CHS infusion and renal dysfunction was found. Moderate and severe hypernatremia was associated with a higher risk of elevated blood urea nitrogen and creatinine levels. Acute renal failure was not seen in these patients. A total of 53.3% in the CHS group and in 16.3% in the NS group (p < 0.0001) had raised ICP (>25 mm Hg), consistent with the physicians decision to use CHS in patients with elevated ICP. CONCLUSIONS: CHS therapy was not associated with an increased rate of infection, deep vein thrombosis, or renal failure. However, there was a significant risk of developing hypernatremia. We conclude that CHS administration in patients with severe injuries is safe as long as sodium levels are carefully monitored.


Asunto(s)
Lesiones Encefálicas/terapia , Solución Salina Hipertónica/efectos adversos , Accidente Cerebrovascular/terapia , Hemorragia Subaracnoidea/terapia , Lesiones Encefálicas/fisiopatología , Enfermedad Crítica , Femenino , Humanos , Riñón/fisiopatología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Solución Salina Hipertónica/administración & dosificación , Solución Salina Hipertónica/uso terapéutico , Accidente Cerebrovascular/fisiopatología , Hemorragia Subaracnoidea/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...